ReviewFuture oncology (London, England)2018
Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Review in Future oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Application of immune checkpoint inhibitors in hepatocellular carcinoma: a landscape analysis of clinical trial databases.Frontiers in immunology · 2026Article
- A new 1,2,3-triazole-indirubin hybrid suppresses tumor growth and pulmonary metastasis by mitigating the HGF/c-MET axis in hepatocellular carcinoma.Journal of advanced research · 2025Article
- Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Identification and neuroprotective properties of NA-184, a calpain-2 inhibitor.Pharmacology research & perspectives · 2024Article
- Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis.Frontiers in oncology · 2024Review
- Lymphoepithelioma-like Hepatocellular Carcinoma: a Case Report and Review of Literature.Journal of gastrointestinal cancer · 2023Review
- Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact.Cancers · 2022Review
- Bioinformatics analysis of immune infiltrates and tripartite motif (Journal of gastrointestinal oncology · 2022Article
- mOxidative medicine and cellular longevity · 2022Article
- Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.Frontiers in immunology · 2022Article
- TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8Cell death & disease · 2021Article
- Progress in hepatectomy for hepatocellular carcinoma and peri-operation management.Genes & diseases · 2020Review
- Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma.International journal of molecular sciences · 2020Article
- Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.American journal of cancer research · 2020Review
- The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology · 2020Review
- Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography.iScience · 2019Article
- From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2019Review
- Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma.Journal of interventional medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Systemic treatments for advanced hepatocellular carcinoma (HCC) are evolving rapidly and several multi-targeted tyrosine kinase inhibitors have demonstrated a survival advantage over best supportive care. Despite these treatment advances, the majority of HCC patients will progress on tyrosine kinase inhibitor therapy. Preclinical data indicate that interference with immune checkpoint molecules results in HCC growth suppression. Several clinical trials applying monoclonal antibodies to immune checkpoint molecules have demonstrated durable antitumor activity in advanced HCC patients. As such, pivotal clinical trials are now in progress to assess if these agents will alter the natural history of the disease and further extend the overall survival of advanced HCC patients. This manuscript will review the current status of immune checkpoint blockade in patients with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.